Author | Jack Arnold, MBBS, MRCP

In SLE, higher doses of prednisolone and the use of immunosuppressive agents, such as cyclophosphamide, have been associated with higher rates of infective sequelae.

As treatment options expand in SLE with an increasing number of targeted therapeutics, we can be optimistic about the potential to improve disease outcomes.

The utility of calculating interferon scores in SLE has generated considerable discourse amongst rheumatologists.

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.